tbuckley/cabot-search huggingface dataset:
Learning child psychiatry skills on the adult inpatient service
Authors: K S Robson, S Cerny, G Adler, A Marks, R Blacher
Journal: American Journal of Psychiatry (1977)

Integration of child psychiatry training into general psychiatric residency programs is often unsuccessful. The authors describe an innovative model of training in child psychiatry that involves the children of adult inpatients. This model offers several advantages: splitting of child-adult psychiatric training is avoided, child diagnostic and evaluative skills tend to be learned rapidly, preventive orientations develop, and family process is both learned and used. Preliminary experience with this model on two inpatient services suggests that it is both didactically effective and economical in child psychiatry staff hours.
Rate and Equilibrium Constants for the Reaction of Maleic Anhydride with the Methyl-1,2-Benzanthracenes&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Melvin S. Newman, Sei Otsuka
Journal: JNCI Journal of the National Cancer Institute (1958)

The adducts of maleic anhydride and 1,2-benzanthracene, 9,10-dimethyl-1,2-benzanthracene and the twelve methyl-1,2-benzanthracenes were prepared. Second order rate constants for the reaction of these hydrocarbons with maleic anhydride in toluene at 100° C. were determined, as well as equilibrium constants at 180° in xylene. No correlation between these rate or equilibrium constants and recently determined carcinogenic activity of the hydrocarbons was observed.
Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993.
Authors: B Coiffier, T Philip, A K Burnett, M L Symann
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.1.226 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7903691 Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993. B CoiffierxB CoiffierSearch for articles by this author , T PhilipxT PhilipSearch for articles by this author , A K BurnettxA K BurnettSearch for articles by this author , M L SymannxM L SymannSearch for articles by this author Show More Service d'Hématologie, Centre Hospitalier Lyon-Sud, Pierre-Benite, France. https://doi.org/10.1200/JCO.1994.12.1.226 First Page PDF © 1994 by American Society of Clinical Oncology
EPT-09TANDEM THIOTEPA-BASED CONDITIONING AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN CHILDREN WITH HIGH-RISK CENTRAL NERVOUS SYSTEM TUMORS
Authors: Vidmante Daylidite, George Mentkevich, Igor Dolgopolov, Andrey Levashov, Stepan Babelyan, Nataly Subbotina
Journal: Neuro-Oncology (2016)
Bevacizumab maintenance (BM) in first line treatment for metastatic breast cancer (MBC): A multicenter retrospective observational study.
Authors: Lucia Mentuccia, Alessandra Fabi, Alessandra Cassano, Patrizia Vici, Andrea Michelotti, Isabella Sperduti, Maria Giuseppa Sarobba, Paolo Marchetti, Ernesto Rossi, Valentina Sini, Maria Teresa Scognamiglio, Domenica Pellegrini, Jamara Giampietro, Angela Vaccaro, Arianna Pellegrino, Laura Pizzuti, Michela Palleschi, Luca I. Moscetti, Dario Nicoletta, Teresa Gamucci
Journal: Journal of Clinical Oncology (2015)

549 Background: Bevacizumab (B) combined with paclitaxel (P) is a treatment option in MBC patients (pts). This multicenter observational study was performed in order to evaluate activity of both B-P association and BM after P discontinuation in real world MBC pts. Methods: 280 MBC pts treated with weekly dose of P with B, with or without BM after P discontinuation were enrolled from 11 Italian cancer centres and retrospectively evaluated. Firstly, the RR for B-P was calculated, and secondly the PFS and OS were evaluated for all pts and separately for pts with/without BM. Chi-square and Fisher Exact tests were used to evaluate possible associations. OS and PFS were calculated by the Kaplan-Meier product-limit method. Log-rank and Tarone-Ware tests were used to assess differences between subgroups. Results: pts median age was 56 yrs (range 27-82), PS 0/1-2 66/44%, ER/PgR positive 83%, TNBC 17%, prior neo/adjuvant taxanes 73%, visceral involvement 60% and bone metastasis alone 11.4%. The median administrations of P and B per pts were respectively 18 (1–39) and 14 (1-52). 14.6% of pts are still receiving B-P and 16.8% pts having PD during B-P are not evaluable for BM. Of the remaining 192 pts, 51.7% received BM after P interruption (withBM). At a median follow-up of 20 mo (range 2-90) 10% pts achieved CR, 54% PR, 18% SD and 12% PD. Disease control rate (CR+PR+SD ≥ 6 m) occurred in 74% pts. The RR was significantly different between ER/PgR pos and TNBC (p = 0.03), which had RR respectively of 71% and 52%. No significant difference was found between pts with or without P pretreatment, nor between different P schedules. Overall, median PFS was 14 mo (95% CI, 12-16) and median OS was 41mo (95% CI 30-51). The median duration of BM was 6 mo (range 2-40). A significant difference was highlighted when comparing median PFS among pts withBM (18 mo, 95%CI 16-20) and withoutBM (13 mo 95% CI 7-18). The median OS was 55mo (95% CI 41-69) in pts withBM and 40 mo (95% CI 29-51) in pts withoutBM: the two groups did not differ significantly. Conclusions: Our analysis showed that the pts withBM after B-P combination had statistically and clinical significant improvement in PFS. Data collection is ongoing and update results will be presented.
ATPS-26ONCOLYTIC VECTORS BASED ON HSV FOR TREATMENT OF GBM
Authors: Paola Sette, Aofei Li, Marco Marzulli, Mingdi Zhang, William Goins, Balveen Kaur, Chelsea Bolyard, Mike Caligiuri, Timothy Cripe, Antonio Chiocca, Nduka Amankulor, Joseph Glorioso, Paola Grandi
Journal: Neuro-Oncology (2015)

Early phase human clinical trials using several versions of oncolytic herpes simplex virus type 1 (oHSV) have shown promise in the treatment of GBM, but efficacy has been limited. Impediments to oHSV therapy include poor virus spread due in part to the tumor extracellular matrix, and insufficient replication in tumor cells as a result of attenuating mutations. Thus, the central goal of this project is to improve oncolytic vector delivery, replication and spread while maintaining safety and tumor specificity. We have already developed a new class of two stage tumor targeted oHSV combining (i) selective infection through tumor-specific receptors and (ii) selective replication based on differential expression of microRNAs (miRs) in tumor and normal cells. We further modify our vector by arming with the matrix metalloproteinase 9 (MMP9) as a means to reduce vector trapping in the tumor extracellular matrix. Data will be presented on the effect the effect of oHSV on the tumor microenvironment.
The National Academies of Sciences, Engineering, and Medicine Report on Bullying
Authors: Megan A. Moreno, Tracy Vaillancourt
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Outbreak of tularaemia in central Norway, January to March 2011
Authors: K W Larssen, J E Afset, B  T Heier, T Krogh, K Handeland, T Vikøren, K Bergh
Journal: Eurosurveillance (2011)

From January to March 2011, 39 cases of tularaemia were diagnosed in three counties in central Norway: 21 cases of oropharyngeal type, 10 cases of glandular/ulceroglandular type, two of respiratory and two of typhoid type. Three cases were asymptomatic and clinical information was unavailable for one case. The mean age was 40.3 years (range 2-89 years). Thirty-four reported use of drinking water from private wells. An increased rodent (lemming) population and snow melting may have led to contamination of the wells with infected rodents or rodent excreta.
Integrating mobile Health (mHealth) Information Technology for the safe administration of chemotherapy (CT)
Authors: E. Galligioni, S. Caramatti, M. Sandri, M. Galvagni, D. Zanolli, M. Sannicolò, A. Ferro, L. Bragantini, F. Maines, C. Trentin, C. Pellegrini, D. Sandri, J. Santi, O. Caffo
Journal: Annals of Oncology (2015)
CR-09QUALITY-OF-LIFE AFTER PENCIL BEAM SCANNING PROTON THERAPY FOR PEDIATRIC CRANIOPHARYNGIOMA PATIENTS TREATED AT PAUL SCHERRER INSTITUTE
Authors: Damien Charles Weber, Alessia Pica, Carmen Teske, Ulrike Kliebsch, Ralf Schneider, Katja Baust, Gabriele Calaminus, Beate Timmermann
Journal: Neuro-Oncology (2016)
Favorable Outcome For Patients With Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine Treosulfan, Compared With Other Reduced Intensity Conditioning Regimen
Authors: Ronit Yerushalmi, Noga Shem-Tov, Yulia Volchek, Ivetta Danylesko, Abraham Avigdor, Arnon Nagler, Avichai Shimoni
Journal: Blood (2013)
CR-22EARLY OUTCOMES OF ENDOSCOPIC EXTENDED TRANSSPHENOIDAL SURGERY FOR CRANIOPHARYNGIOMAS IN CHILDREN
Authors: M. Javadpour, S. Giva, C. Costigan, J. Caird, D. Crimmins, M. Capra, J. Pears, C. Owens, D. Brosnahan, C. O'Sullivan, D. Cody
Journal: Neuro-Oncology (2016)
Soundings: The people vote; the doctor calls
Authors: George Dunea
Journal: BMJ (1998)

It seems that Americans have had enough of Miss Lewinsky. Instead they voted in the last election for middle of the road candidates and sound government, and against right and left wing extremists and puritans. In local elections they likewise chose moderate candidates. In Minnesota, however, they made an unusual choice in electing the Reform Party candidate, who trounced other candidates for governor on a platform of lower taxes and less spending, but also legal recognition of gay relationships, looser gun laws, and possibly legalising prostitution.

Also of interest were the outcomes of some 235 state or local ballots: Washington state joined California in banning affirmative action programmes based on gender or race. Three states approved medical use of marijuana; two approved gambling on boats or Indian reservations; two rejected bans on late, so called “partial abortion;” and three rejected same sex marriage.

Several states rejected tax raising measures, but two approved building new stadiums. Proanimal or environment measures included restrictions on expanding hog farms, using cyanide in some forms of gold mining, using steel traps to catch fur bearing animals, and exporting out of state horses intended to be slaughtered for human consumption. But Alaska rejected banning wolf snares, and other states voted against imposing various restrictions on hunting and fishing. Two states formally acknowledged women’s equality, but New Hampshire retained male pronouns in its constitution, even though its governor is a she.

In Cook County voters approved by a large majority an amendment declaring health care a “basic human right.” Initiated by supporters of a single payer system, this proposition is advisory and non-binding, to be considered by the state legislature. Meanwhile we read that the house call is back, as more doctors visit their sick patients, many of whom are elderly (mean age 78) with chronic or even terminal illnesses. But now the black leather bag has given way to high tech equipment in the doctor’s car. Less expensive than hospital care and vastly preferable for debilitated patients who cannot get around easily, a house call is certainly nicer and more convenient than waiting for hours in an unfriendly, overcrowded emergency room.
What <i>is</i> teaching? A clear, integrative, operational definition for teaching is still needed
Authors: Yonat Eshchar, Dorothy Fragaszy
Journal: Behavioral and Brain Sciences (2015)

The study of teaching indeed suffers from multiple approaches built upon disparate views. Kline does an excellent job in explaining the problem, but does not go all the way towards solving it. We suggest that a better operational definition, which could be utilized both in human studies and animal studies, is needed to integrate the field truly.
Reduced cyclic AMP production in the blood platelets from schizophrenic patients
Authors: M S Kafka, D P van Kammen, W E Bunney
Journal: American Journal of Psychiatry (1979)

The authors assessed alpha-adrenergic receptor function in blood platelets from chronic schizophrenic patients and normal control subjects. The number of receptors was measured by the specific binding of the alpha-adrenergic antagonist [3H]dihydroergocryptine to the platelets. A physiological response of the platelets to agonist occupancy of the alpha-adrenergic receptors was measured by the norepinephrine inhibition of prostaglandin E1(PGE1)-stimulated cyclic AMP (cAMP) production. cAMP production in male schizophrenic patients was lower than in normal male subjects. alpha-Adrenergic receptor function was similar in patients and normal control subjects of both sexes. Normal male subjects had about 1.5 times the number of alpha-adrenergic receptors as normal females and generated about 1.8 times the quantity of PGE1-stimulated cAMP.
Do glucocorticoids influence the survival of myeloma patients?
Authors: D E Bergsagel
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.4.1045 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7707103 Do glucocorticoids influence the survival of myeloma patients? D E BergsagelxD E BergsagelSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.4.1045 First Page PDF © 1995 by American Society of Clinical Oncology
Acne vulgaris: an inflammasomopathy of the sebaceous follicle induced by deviated FoxO1/ <scp>mTORC</scp> 1 signalling
Authors: B.C. Melnik
Journal: British Journal of Dermatology (2016)

Linked Article: Agamia et al. Br J Dermatol 2016; 174: 1299–1307.
Nature of Glutamate Alterations in Schizophrenia
Authors: Kate Merritt, Alice Egerton, Matthew J. Kempton, Matthew J. Taylor, Philip K. McGuire
Journal: JAMA Psychiatry (2016)

Alterations in glutamatergic neurotransmission may be fundamental to the pathophysiology of schizophrenia, and the glutamatergic system is a target for novel therapeutic interventions in the disorder.To investigate the nature of brain glutamate alterations in schizophrenia by conducting a meta-analysis of glutamate proton magnetic resonance (MRS) spectroscopy studies.The MEDLINE database was searched for studies published from January 1, 1980, to April 1, 2015. Search terms included magnetic resonance spectroscopy, schizophrenia, psychosis, clinical or genetic high risk, and schizoaffective. Inclusion criteria were single voxel 1H-MRS studies reporting glutamate, glutamine or Glx values for a patient or risk group in comparison to a healthy volunteer group.Fifty-nine studies were identified, which included 1686 patients and 1451 healthy individuals serving as controls.A random-effects, inverse-weighted variance model was used to calculate the pooled effect size. Mean values were extracted and verified independently. Effect sizes were determined for glutamate, glutamine, and Glx in brain regions that had been examined in at least 3 different studies. A secondary analysis grouped studies into those examining patients at different stages of illness (high risk, first-episode psychosis, or chronic schizophrenia). Effects of age, antipsychotic dose, and symptom severity were determined using meta-regression.In schizophrenia, there were significant elevations in glutamate in the basal ganglia (Hedges g = 0.63; 95% CI, 0.15-1.11), glutamine in the thalamus (g = 0.56; 95% CI, 0.02-1.09), and Glx in the basal ganglia (g = 0.39; 95% CI, 0.09-0.70) and medial temporal lobe (g = 0.32; 95% CI, 0.12-0.52). No region showed a reduction in glutamate metabolites in schizophrenia. Secondary analyses revealed that elevated medial frontal Glx levels were evident in individuals at high risk for schizophrenia (g = 0.26; 95% CI, 0.05-0.46) but not in those with first-episode psychosis or chronic schizophrenia, whereas elevated Glx in the medial temporal lobe was seen with chronic schizophrenia (g = 0.40; 95% CI, 0.08-0.71) but not in the high-risk or first-episode groups. Meta-regression found no association with age, symptom severity, or antipsychotic dose.Schizophrenia is associated with elevations in glutamatergic metabolites across several brain regions. This finding supports the hypothesis that schizophrenia is associated with excess glutamatergic neurotransmission in several limbic areas and further indicates that compounds that reduce glutamatergic transmission may have therapeutic potential.
Case 1-1981
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, William C. Wood, Jaime Part
Journal: New England Journal of Medicine (1981)

Presentation of CaseA 79-year-old woman was admitted to the hospital because of an abdominal mass.She was in excellent health until 16 months earlier, when she began to have vague pain in the right side of the abdomen. A physician found mild right abdominal tenderness, without other abnormality. Her weight was 64 kg. The hematocrit was 38.8 per cent. A barium-enema examination and an oral cholecystographic study were negative. Her symptoms appeared to improve. Six months before admission she again experienced right abdominal pain, accompanied by fatigue and anorexia. Three months later examination revealed right abdominal tenderness. Her weight . . .
HG-24GLUCOCORTICOID-MEDIATED EPIGENOMIC REVERSAL IN DIFFUSE INTRINSIC PONTINE GLIOMAS
Authors: Jamila Gittens, Sridevi Yadavilli, Madhuri Kambhampati, Jesse Damsker, Oren J. Becher, Nalin Gupta, Roger J. Packer, Javad Nazarian
Journal: Neuro-Oncology (2016)
Status Report on Saccharin in Humans
Authors: Guy R. Newell, M.D., Robert N. Hoover, M.D., Albert C. Kolbye, Jr., M.D.
Journal: JNCI Journal of the National Cancer Institute (1978)

On the basis of experimental evidence that the artificial sweetener saccharin causes bladder cancer in rodents (1-6), on April 15, 1977, the FDA proposed a ban on saccharin.Under existing law, any substance known to cause cancer in animals or man cannot be allowed on the market as a food additive, so the FDA had no choice in its proposed ban.Saccharin is the only nonsugar sweetener on the market, and the public perceives that it benefits fropt having it available.Because of this perception, the proposed saccharin ban caused a public outcry that was reflected in mail, telegrams, and telephone calls to members of Congress.Congressional hearings on this subject were held in March and June 1977.In December 1977, Congress imposed an IS-month moratorium on the proposed ban so that more information could be collected.During the hearings questions arose such as: the rationale for equating carcinogenicity in mice, rats, and other lower animals with carcinogenicity in humans; the justification for administering large unphysiologic doses of a material that presumably do not equate to the lower dose used naturally by humans; and the validity of extrapolating the results of large doses in animals to the situation in humans.The answers to these questions relate to the life-spans of the animals, metabolic rates of lower animals compared to those of humans, and the intent of bioassay tests to demonstrate carcinogenicity if it exists rather than one's missing it or attempting to quantify the level of risk.Answers to these questions are based on the knowledge that all known carcinogens in man (occurring from natural experiments such as occupational exposures) also cause cancer in some lower animal systems.Two possible exceptions are arsenic and benzene.It is not known whether the reverse is true, namely, that substances carcinogenic for lower animals are necessarily carcinogenic for humans.This proposition would be impossible to prove one way or the other at this time.Precise determinations of thresholds for carcinogens are not attainable at the present time, although the evidence is mounting that, as the dose of many carcinogens is increased, additional factors in terms of cancer causation come into play that may be avoidable at lower doses.Also, for some carcinogens evidence suggests that the carcinogenic response is secondary to a primary response that can be prevented by minimizing exposures.About the same time that the FDA proposed to ban saccharin, a Canadian study of humans suggested that men with bladder cancer were more frequent users of
Donor Diary
Authors: George L Higgins
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HG-23BET INHIBITORS WORK SYNERGISTICALLY WITH PANOBINOSTAT IN TREATING DIFFUSE INTRINSIC PONTINE GLIOMA
Authors: Yujie Tang, Surya Nagaraja, Nicholas A. Vitanza, Pamelyn Woo, Anitha Ponnuswami, Michelle Monje
Journal: Neuro-Oncology (2016)

Diffuse intrinsic pontine glioma (DIPG) is a devastating childhood brain tumor with a median survival of 9 months.Epigenetic dysregulation has been shown to play a critical role in DIPG pathogenesis since the identification of H3-K27M mutation.We have recently reported that the histone deacetvlase inhibitor (HDACi) panobinostat is effective in treating DIPG in preclinical models, suggesting epigenetic therapy could be a promising strategy for Overall survival Key Inclusion Criteria Key Exclusion Criteria LEARN MOREimvax.com/patients-families